Hepatocellular carcinoma (HCC) is a malignant tumor associated with high global incidence and mortality rates. Proteomics,as a platform technology of cellular protein expression, modification, and interaction, has pro...Hepatocellular carcinoma (HCC) is a malignant tumor associated with high global incidence and mortality rates. Proteomics,as a platform technology of cellular protein expression, modification, and interaction, has provided innovativeperspectives on early diagnosis, treatment, and targeted drug development for HCC. This review summarizes recentprogress in proteomics for advancing HCC biomarker discovery, drug target identification, and understanding drugaction mechanisms. Proteomic technologies, including mass spectrometry for specific protein signatures identification,protein microarrays for high-throughput analysis, and bioinformatics for data interpretation, have profoundlypromoted the identification of liver cancer-specific biomarkers. These advancements not only facilitate early diagnosisbut also improve prognostic assessment. Proteomics is pivotal in expediting the discovery and development of newdrugs, providing more effective and personalized treatment options for HCC patients. This review offers a comprehensiveoverview of the applications of proteomics in anti-HCC drug research, serving as a reference to further advancethe development of HCC research and treatment domains.展开更多
Mass cytometry(cytometry by time-of-flight(CyTOF))and imaging mass cytometry(IMC)are transformative technologies that combine flow cytometry principles with time-of-flight mass spectrometry(TOF-MS).By employing metal ...Mass cytometry(cytometry by time-of-flight(CyTOF))and imaging mass cytometry(IMC)are transformative technologies that combine flow cytometry principles with time-of-flight mass spectrometry(TOF-MS).By employing metal isotope-tagged antibodies instead of fluorophores,these techniques overcome spectral overlap limitations and enable high-dimensional,compensation-free analysis of complex biological systems at single-cell resolution.The performance of CyTOF and IMC critically depends on advanced nanomaterials labeled with stable metal isotopes,which are essential for improving sensitivity and multiplexing capacity.This review systematically discusses the design principles,synthesis methods,and functionalization strategies of mass-tagged nanomaterials tailored for CyTOF(e.g.,cell suspension analysis)and IMC(e.g.,spatial proteomics of tissue sections).We highlight their impactful applications in biomedicine,including proteomics,immunology,oncology,and neuroscience,emphasizing their roles in disease diagnosis,targeted drug development,and singlecell analysis.Despite these advancements,challenges such as nanomaterial biocompatibility,clinical scalability,and artificial intelligence(AI)-driven design are discussed,providing a roadmap for future research in personalized medicine and theranostics.展开更多
基金supported by National Key Research and Development Program of China(2022YFC2601700,2022YFF0710202 and 2022YFA1104200)National Natural Science Foundation of China(T2122002,82361148715,22077079,82204104),WADA Research Grant(22B05PC)+3 种基金Shanghai Municipal Science and Technology Project(22Z510202478)Shanghai Municipal Education Commission Project(21SG10,ZXWH1082101)Shanghai Jiao Tong University Project(YG2021ZD19)Shanghai University of Medicine&Health Sciences Project(AMSCP-24-07-01).
文摘Hepatocellular carcinoma (HCC) is a malignant tumor associated with high global incidence and mortality rates. Proteomics,as a platform technology of cellular protein expression, modification, and interaction, has provided innovativeperspectives on early diagnosis, treatment, and targeted drug development for HCC. This review summarizes recentprogress in proteomics for advancing HCC biomarker discovery, drug target identification, and understanding drugaction mechanisms. Proteomic technologies, including mass spectrometry for specific protein signatures identification,protein microarrays for high-throughput analysis, and bioinformatics for data interpretation, have profoundlypromoted the identification of liver cancer-specific biomarkers. These advancements not only facilitate early diagnosisbut also improve prognostic assessment. Proteomics is pivotal in expediting the discovery and development of newdrugs, providing more effective and personalized treatment options for HCC patients. This review offers a comprehensiveoverview of the applications of proteomics in anti-HCC drug research, serving as a reference to further advancethe development of HCC research and treatment domains.
基金supported by National Natural Science Foundation of China(T2122002,82361148715,22077079,82204104)National Key R&D Program of China(2022YFC2601700,2022YFF0710202 and 2022YFA1104200)+4 种基金Princess Nourah bint Abdulrahman University Researchers Supporting Project number(PNURSP2024R122)Shanghai Municipal Science and Technology Projects(22Z510202478)Shanghai Municipal Education Commission Projects(21SG10,ZXWH1082101)Shanghai Jiao Tong University Projects(YG2021ZD19)Shanghai University of Medicine&Health Sciences Project(AMSCP-24-07-01).
文摘Mass cytometry(cytometry by time-of-flight(CyTOF))and imaging mass cytometry(IMC)are transformative technologies that combine flow cytometry principles with time-of-flight mass spectrometry(TOF-MS).By employing metal isotope-tagged antibodies instead of fluorophores,these techniques overcome spectral overlap limitations and enable high-dimensional,compensation-free analysis of complex biological systems at single-cell resolution.The performance of CyTOF and IMC critically depends on advanced nanomaterials labeled with stable metal isotopes,which are essential for improving sensitivity and multiplexing capacity.This review systematically discusses the design principles,synthesis methods,and functionalization strategies of mass-tagged nanomaterials tailored for CyTOF(e.g.,cell suspension analysis)and IMC(e.g.,spatial proteomics of tissue sections).We highlight their impactful applications in biomedicine,including proteomics,immunology,oncology,and neuroscience,emphasizing their roles in disease diagnosis,targeted drug development,and singlecell analysis.Despite these advancements,challenges such as nanomaterial biocompatibility,clinical scalability,and artificial intelligence(AI)-driven design are discussed,providing a roadmap for future research in personalized medicine and theranostics.
